Thursday, June 21, 2012

Bharat Biotech receives $ 4 million award from The Wellcome Trust

HYDERABAD: Vaccine manufacturer Bharat Biotech (Dr. Krishna Ella, Chairman and Managing  Director) and The University of Maryland Center for Vaccine Development (CVD) have received $ 4 million from The Wellcome Trust for clinical development of a new conjugate vaccine for treating an infectious disease.

The Trust will also fund clinical trials beginning in three years to prevent the potentially lethal infectious disease caused by invasive non-typhoidal Salmonella (NTS). This strain is most common in the sub Saharan African regions among malnourished children. About 20-30% of the children are known to die because of this infectious disease each year.

"The impact, importance of academic and industry partnership is far reaching," Dr. Krishna Ella, chairman and managing director, Bharat Biotech said. "The CVD NTS project is a testimony of our belief in collaborative research and our commitment to introduce highly effective and affordable vaccines to solve region specific neglected diseases in the developing world."

The University of Maryland Center for Vaccine Development has brought in significant grant funding over the past few decades to support its extensive vaccine development programs. This vaccine programme is a public-private partnership programme and the CVD has been engaged in research in vaccinology since 1974. Bharat Biotech is focussed on developing novel vaccines for region specific neglected diseases in compliance with Global IPR. It has already markets products such as REVAC-B, REGEN-D, HNVAC, etc, and vaccine candidates against
rotavirus, typhoid fever, Japanese encephalitis, chikungunya etc.
Post a Comment